Anja Sophie Schmid1, Teresa Hemmerle2, Francesca Pretto2, Anja Kipar3, Dario Neri1. 1. Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland. 2. Philochem AG, Otelfingen, University of Zürich, Zürich, Switzerland. 3. Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.
Abstract
Objectives: We have previously reported that F8-IL4, a fusion protein consisting of the F8 antibody specific to the alternatively-spliced extra domain A of fibronectin and of murine IL-4, cures mice with established arthritis, when used in combination with dexamethasone (DXM). The goal of this study was to assess whether other therapeutic agents, besides DXM, could induce cures in combination with F8-IL4 and to elucidate which leucocytes are most affected by the pharmacological treatment. Methods: We performed therapy experiments in mice with CIA, using intravenous administrations of F8-IL4 in combination with DXM, MTX, murine cytotoxic T-lymphocyte-associated protein 4 fused to the fragment crystallizable portion of murine IgG2a, as well as mAbs to murine IL17A or the p40 subunit of murine IL12/IL23. Histology and immunohistochemistry for the identification of the various leucocytes were performed on the paws of mice euthanized at different therapy time points. Results: Only the use of F8-IL4 in combination with DXM induced complete remissions, while all other combinations did not lead to cures. The light microscopical evaluation of paws with arthritis revealed a predominant infiltration of neutrophils, which substantially decreased 24 h after treatment with F8-IL4 and DXM. Conclusion: The combination of F8-IL4 with DXM promotes a rapid anti-arthritic action by potently inhibiting neutrophil activity. A fully human analogue of F8-IL4 may find clinical utility for the treatment of neutrophil-driven chronic inflammatory conditions.
Objectives: We have previously reported that F8-IL4, a fusion protein consisting of the F8 antibody specific to the alternatively-spliced extra domain A of fibronectin and of murine IL-4, cures mice with established arthritis, when used in combination with dexamethasone (DXM). The goal of this study was to assess whether other therapeutic agents, besides DXM, could induce cures in combination with F8-IL4 and to elucidate which leucocytes are most affected by the pharmacological treatment. Methods: We performed therapy experiments in mice with CIA, using intravenous administrations of F8-IL4 in combination with DXM, MTX, murine cytotoxic T-lymphocyte-associated protein 4 fused to the fragment crystallizable portion of murine IgG2a, as well as mAbs to murine IL17A or the p40 subunit of murine IL12/IL23. Histology and immunohistochemistry for the identification of the various leucocytes were performed on the paws of mice euthanized at different therapy time points. Results: Only the use of F8-IL4 in combination with DXM induced complete remissions, while all other combinations did not lead to cures. The light microscopical evaluation of paws with arthritis revealed a predominant infiltration of neutrophils, which substantially decreased 24 h after treatment with F8-IL4 and DXM. Conclusion: The combination of F8-IL4 with DXM promotes a rapid anti-arthritic action by potently inhibiting neutrophil activity. A fully human analogue of F8-IL4 may find clinical utility for the treatment of neutrophil-driven chronic inflammatory conditions.
Authors: Ruth Klaasen; Rogier M Thurlings; Carla A Wijbrandts; Arno W van Kuijk; Dominique Baeten; Danielle M Gerlag; Paul P Tak Journal: Arthritis Rheum Date: 2009-11
Authors: Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg Journal: Arthritis Rheum Date: 2004-02
Authors: Diahann T S L Jansen; Hanane el Bannoudi; Ramon Arens; Kim L L Habets; Marjolijn Hameetman; Tom W J Huizinga; Jeroen N Stoop; René E M Toes Journal: Arthritis Res Ther Date: 2015-08-20 Impact factor: 5.156
Authors: Santa Mammana; Paolo Fagone; Eugenio Cavalli; Maria Sofia Basile; Maria Cristina Petralia; Ferdinando Nicoletti; Placido Bramanti; Emanuela Mazzon Journal: Int J Mol Sci Date: 2018-03-13 Impact factor: 5.923
Authors: Ana L Carvalho; Sonia Fonseca; Ariadna Miquel-Clopés; Kathryn Cross; Khoon-S Kok; Udo Wegmann; Katherine Gil-Cordoso; Eleanor G Bentley; Sanaria H M Al Katy; Janine L Coombes; Anja Kipar; Regis Stentz; James P Stewart; Simon R Carding Journal: J Extracell Vesicles Date: 2019-06-24